Prospective Randomized Study Comparing Docetaxel, Estramustine, and Prednisone With Docetaxel and Prednisone in Metastatic Hormone-Refractory Prostate Cancer

Machiels, Jean‐Pascal; Mazzeo, F; Clausse, Marylene; Filleul, Bertrand; Marcelis, Luc; Honhon, Brigitte; D’Hondt, Lionel; Dopchie, Catherine; Verschaeve, Vincent; Duck, Lionel; Verhoeven, Didier; Jousten, Peter; Bonny, Marie-Alix; Moxhon, Anne-Marie; Tombal, Bertrand; Kerger, Joseph

doi:10.1200/jco.2008.16.9524

Cited by 79 publications

(44 citation statements)

References 25 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…However, a recent randomized trial comparing docetaxel, estramustine and prednisone with docetaxel and prednisone [24] has shown that the combination of docetaxel and estramustine has no apparent effect either on PSA response rate (73% versus 69%) or on survival (median 19.3 versus 21 months), with a poorer toxicity profile.…”

Section: Discussionmentioning

confidence: 99%

Efficacy of carboplatin–taxane combinations in the management of castration-resistant prostate cancer: a pooled analysis of seven prospective clinical trials

et al. 2010

View full text Add to dashboard Cite

Background: Docetaxel is associated with prolonged survival in castration-resistant prostate cancer (CRPC).Platinum compounds have modest but distinct single-agent activity. Carboplatin may have greatest potential for benefit when combined with taxanes. We investigated whether there is a subset of patients with CRPC for whom the efficacy of combination taxane-estramustine-carboplatin (TEC) chemotherapy may be greatest.Patients and methods: Individual patient data (n = 310) were obtained from seven trials using TEC chemotherapy.Prostate-specific antigen (PSA) response was defined as ‡50% post-therapy decline from baseline. Overall survival was defined from baseline to death from any cause. Logistic and Cox regression were used to investigate heterogeneity in outcome to TEC by patient and disease characteristics. Predicted survival probabilities were calculated from the Halabi Cancer and Leukemia Group B (CALGB) nomogram. Results:The pooled PSA response proportion was 69% [95% confidence interval (CI) 56% to 80%]. There was no evidence of differential PSA response by disease characteristics. Established prognostic factors were associated with survival. The pooled 12-month survival estimate of 79% (95% CI 71% to 84%) was higher than the median 59% 12-month nomogram-predicted survival.Conclusions: TEC chemotherapy has significant clinical activity in CRPC. A randomized, controlled trial evaluating the addition of carboplatin to taxane-based chemotherapy is needed to elucidate the value of carboplatin in CRPC.

show abstract

Section: Discussionmentioning

confidence: 99%

Efficacy of carboplatin–taxane combinations in the management of castration-resistant prostate cancer: a pooled analysis of seven prospective clinical trials

et al. 2010

View full text Add to dashboard Cite

show abstract

“…Chemotherapy has only limited efficacy in AIPC and HRPC (12). During androgen-dependent progression, prostate cancer cells depend on the androgen receptor as the primary mediator of growth and survival.…”

Section: ------------------------------------------------------------mentioning

confidence: 99%

Comparison of protein expression in two prostate cancer cell-lines, LNCaP and DU145, after treatment with somatostatin

Liu

Márquez²,

Nilsson³

et al. 2009

Oncol Rep

View full text Add to dashboard Cite

Abstract. The mechanisms underlying prostate cancer progression are poorly understood. Proteins responsive to androgens may be involved in the development and progression of prostate cancer and the ultimate failure of androgen-ablation therapy. Therapy with somatostatin (sms) analogues could be a possible therapeutic alternative to chemotherapy in hormone refractory prostate cancer patients. We used two prostate cancer cell-lines, LNCaP (androgendependent) and DU145 (androgen-independent), to compare the protein expressions. Both cell lines were treated with sms and its derivative smsdx. Smsdx is a glycosylated poly sms with high stability suitable for clinical use. A comparison study of protein expression was analyzed by means of twodimensional gel electrophoresis (2DE) followed by mass spectrometric analysis. Marked quantitative differences were observed in the protein expression profiles in sms/smsdx treated LNCaP and DU145 cells compared to the control cells. One third of the detected proteins were differentially expressed (PRDXs, hnRNPs, HSPs, RKIP). Concordance in protein expression patterns was observed between smsdx and sms treated cells with strong agreement between the up-and down-regulation of proteins. Fifty-eight (isoforms of 49 proteins) protein spots were identified and found differentially expressed at 2-fold change between LNCaP and DU145 cells. Thirty-one proteins in LNCaP have higher expressions than in DU145. Twenty-seven proteins in DU145 have higher expressions than in LNCaP. Most of the differentially expressed proteins (2-fold) between LNCaP and DU145 cells were affected by sms/smsdx treatment (1.2-to 2.6-fold change). Sms/smsdx affects the mitochondria of prostate cancer cells in a way that eventually triggers mitochondrialmediated apoptosis. Regulation of certain proteins (e.g., RKIP, VDACs) by sms/smsdx suggests that sms/smsdx exerts its effects on prostate cancer cells via MAPK pathway and by regulating the activities of phosphotyrosine phosphatases. IntroductionProstate cancer is the most common malignancy and the second leading cause of cancer-related mortality in men in the Western world (1). Although androgen ablation is the most effective therapy for patients with advanced prostate cancer, progression to androgen independence (AIPC) and hormone refractory (HRPC) eventually occurs (2). Androgenindependent prostate cancer carries a bleak prognosis with short survival time. AIPC metastasizes preferentially to the skeleton which is associated with considerable morbidity such as pain and fractures.Several pathways provide insights into the mechanism of androgen action and schemes by which cancer cells subvert normal growth control and escape treatment attempts. Understanding the pathways that lead to AIPC will eventually lead to the development of new therapies. In our previous studies (3,4), smsdx (glycosylated poly sms with high stability suitable for clinical use) was found to be able to trigger upregulation of catalytic mitochondrial proteins and seemed to affect apoptotic-related...

show abstract

“…7 Furthermore, the addition of estramustine to docetaxel and prednisone did not provide any clinical advantage and more digestive and cardiovascular toxicities were reported. 8 According to these data, docetaxel plus prednisone is considered the gold standard first-line chemotherapy for CRPC. Unfortunately, median OS for patients affected by metastatic prostate cancer is less than 20 months.…”

Section: Medical Strategies For Treatment Of Castration Resistant Promentioning

confidence: 99%

Medical strategies for treatment of castration resistant prostate cancer (CRPC) docetaxel resistant

Altavilla

Iacovelli

Procopio

et al. 2012

Cancer Biology & Therapy

View full text Add to dashboard Cite

Prospective Randomized Study Comparing Docetaxel, Estramustine, and Prednisone With Docetaxel and Prednisone in Metastatic Hormone-Refractory Prostate Cancer

Abstract: The addition of estramustine to weekly D does not provide any clinically relevant advantage. Both regimens are well tolerated, although the toxicity profile favors D without estramustine.

Cited by 79 publications

References 25 publications

Efficacy of carboplatin–taxane combinations in the management of castration-resistant prostate cancer: a pooled analysis of seven prospective clinical trials

Efficacy of carboplatin–taxane combinations in the management of castration-resistant prostate cancer: a pooled analysis of seven prospective clinical trials

Comparison of protein expression in two prostate cancer cell-lines, LNCaP and DU145, after treatment with somatostatin

Medical strategies for treatment of castration resistant prostate cancer (CRPC) docetaxel resistant

Contact Info

Product

Resources

About